Ajanta Pharma Limited (AJANTPHARM.NS) Stock Analysis & Winston Score

Ajanta Pharma is an Indian pharmaceutical company that makes and sells generic and branded medicines. Its core products include tablets, capsules, and eye drops across therapeutic areas like cardiology, dermatology, malaria treatment, and ophthalmology. The company sells to patients and healthcare providers in India, Africa, Asia, and the United States. Ajanta earns money by selling finished drug products directly to pharmacies, hospitals, and distributors, as well as exporting generic medicines to regulated markets like the US and emerging markets across Africa and Southeast Asia. It is a mid-sized Indian pharma company with a notably high gross margin, reflecting its focus on branded generics where it can charge more than commodity drug makers. Its strong return on capital suggests efficient operations and pricing power in niche therapeutic segments. The key growth driver is expanding its US generics pipeline, while the main risk is regulatory scrutiny from agencies like the US FDA, which can delay or block product approvals.